Recital 63, Regulation (EU) 2026/1386

In forcesince 17 Jun 2026

In order to take into account the adoption or amendment of Union legal acts establishing projects or programmes, to adapt the list of technology areas that are relevant for risk assessments and to take into account the adoption of legal acts providing for the establishment of the Union List of Critical Medicinal Products, the power to adopt acts in accordance with Article 290 TFEU should be delegated to the Commission in respect of amendments to the relevant provisions of this Regulation and the Annexes thereto. The list of projects and programmes of Union interest set out in the relevant Annex to this Regulation should cover projects or programmes established by Union law that provide for the development, maintenance or acquisition of critical infrastructure, critical technologies or critical inputs which are of particular importance for security or public order. The list of technology areas that are relevant for risk assessments set out in the relevant Annex to this Regulation should include areas where a foreign investment could affect security or public order in more than one Member State through a Union target, which does not participate in or receive funds from a project or programme of Union interest. As regards critical medicines, it is important that, when the Commission has established the Union List of Critical Medicinal Products by means of an implementing act adopted pursuant to a Regulation laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulations (EC) No 1394/2007 [OJ L 324, 10.12.2007, p. 121.] and (EU) No 536/2014 [OJ L 158, 27.5.2014, p. 1.] and repealing Regulations (EC) No 141/2000 [OJ L 18, 22.1.2000, p. 1.], (EC) No 726/2004 [OJ L 136, 30.4.2004, p. 1] and (EC) No 1901/2006 [OJ L 378, 27.12.2006, p. 1.], the reference to the critical medicines to be taken into account by Member States and the Commission when determining whether a foreign investment is likely to negatively affect security or public order should be updated and replaced with a reference to the Union List of Critical Medicinal Products and subsequent amendments thereto and that the relevant annex should be deleted. It is of particular importance that the Commission carries out appropriate consultations during its preparatory work, including at expert level and that those consultations be conducted in accordance with the principles laid down in the Interinstitutional Agreement of 13 April 2016 on Better Law-Making [OJ L 123, 12.5.2016, p. 1, ELI: http://data.europa.eu/eli/agree_interinstit/2016/512/oj.]. In particular, to ensure equal participation in the preparation of delegated acts, the European Parliament and the Council receive all documents at the same time as Member States’ experts, and their experts systematically have access to meetings of Commission expert groups dealing with the preparation of delegated acts.